Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new class of drugs called CELMoDs — including iberdomide and mezigdomide — is showing impressive results in multiple myeloma, potentially displacing current standard-of-care regimens. Iberdomide recently received FDA accelerated approval, while mezigdomide nearly doubled progression-free survival in a phase 3 trial. Experts say these agents could be the most exciting immunotherapy advance in the field outside of CAR T-cell therapies.
CELMoDs (cereblon E3 ligase modulators) — including iberdomide and mezigdomide — are emerging as a potentially game-changing drug class in multiple myeloma. Unlike older immunomodulatory drugs (IMiDs), CELMoDs are specifically engineered to target cereblon with greater potency, making them stronger activators of the immune system. Experts like Dr. Jesús Berdeja of Sarah Cannon Research Institute describe them as the most exciting immunotherapy class to emerge in recent years, outside of CAR T-cell therapies and bispecific antibodies.
Clinical trial data backs up the enthusiasm. In prospective studies, combining CELMoDs with standard backbone therapies has consistently outperformed existing standard-of-care regimens, positioning this class to potentially replace some current treatment options.
By the Numbers
Why it matters: With FDA approval already granted for iberdomide and compelling phase 3 data for mezigdomide, CELMoDs are moving from promising to practice-changing — offering patients with relapsed/refractory myeloma meaningfully better outcomes.
